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Abstract 
Background: In previous work, we showed that serum‑free amino acid (SFAA) profiles were different between 
kidney cancer patients and age and sex matched controls. The goals of the current study are to: (1) confirm our initial 
observation on an independent sample set; (2) examine if there were similar differences in plasma‑free amino acids 
(PFAA); and (3) determine if removal of tumors changed SFAA and PFAA profiles.
Methods: SFAA and PFAA profiles were measured in 484 samples taken from 124 healthy controls and 56 clear cell 
renal cell carcinoma (ccRCC) patients both before and after resection of renal tumors.
Results: SFAA and PFAA profiles taken from identical blood samples were remarkably different, with the mean indi‑
vidual amino acid concentrations being 40% less in plasma compared to serum. Both SFAA and PFAA profiles differed 
significantly between ccRCC patients and controls, but the individual amino acids that differed the most, and the 
direction of the changes, were quite different between the two blood components. Removal of the tumor had almost 
no effect on either the SFAA or PFAA profiles. A logistic regression model using serum histidine and plasma trypto‑
phan correctly classified 85.5% of control and 84.7% of case samples.
Conclusions: Our findings show that that tumor mass is not directly linked to alterations in blood amino acid levels, 
and that a combination of serum histidine and plasma tryptophan may be useful as a biomarker to detect ccRCC.
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Background
In the United States, there are over 50,000 cases of renal 
cell carcinoma diagnosed annually resulting in more than 
13,000 deaths [1]. It is the eighth leading cause of cancer 
deaths in men and the fourteenth in woman. Prognosis 
is very much dependent on the stage at which the dis-
ease is caught. Small tumors confined to the kidney (T1) 
have 5-year survival rates as high as 90%, while advanced 
tumors that have metastasized outside the kidney (T4) 
have rates <20% [2]. Unfortunately, most individuals with 
locally confined disease have no obvious symptoms and, 
therefore, the disease is often detected at an advanced 
stage. Increasing the percentage of individuals diagnosed 
with early stage disease would lead to a significant reduc-
tion in mortality from this disease. The development of 
an inexpensive blood based screening test to detect renal 
cell carcinoma would be extremely useful in achieving 
this goal.
Our lab has previously published a study of free amino 
acids in preoperative serum (SFAA) taken from 189 renal 
cell carcinoma patients (65% clear cell) and 104 con-
trols [3]. We found significant differences in 15 of the 26 
amino acids assayed. A logistic regression model using 8 
amino acids was able to distinguish controls from cases 
with an ROC of 0.81. This same model also had predic-
tive value in terms of overall survival and tumor recur-
rence in patients with renal cell carcinoma.
Here, we asked the question if the alterations in SFAA 




*Correspondence:  Warren.Kruger@fccc.edu 
1 Cancer Biology Program, Fox Chase Cancer Center, 333 Cottman 
Avenue, Philadelphia, PA 19111, USA
Full list of author information is available at the end of the article
Page 2 of 6Lee et al. J Transl Med  (2017) 15:72 
directly due to the tumor mass itself, as renal cancer is 
known to have profound effects on cellular metabolism 
[4]. To answer this, we examined SFAA profiles in 56 new 
ccRCC patients that had blood samples taken both before 
and after exenterative surgery. In addition, we examined 
PFAA profiles in the same patients and compared them 
to controls. Our findings indicate that ccRCC patients 
have significant alterations in both PFAA and SFAA pro-




Serum and plasma were obtained from ccRCC patients 
(n = 56) and controls (n = 124) from the Fox Chase Can-
cer Center Biosample Repository (Additional file 1: Table 
S1). For serum, blood was collected in yellow-capped 
serum separating tubes, while plasma blood was col-
lected in acid citrate dextrose vacutainers. Serum and 
plasma were collected at the same time. After process-
ing, all samples were stored at −70 °C. All ccRCC cases 
were FCCC patients with histopathologically confirmed 
clear cell renal cancers who underwent exenterative sur-
gery. Pre-surgical blood was collected within 30 days of 
surgery (56 samples of serum and plasma each). Post-sur-
gical samples were collected after surgery with a median 
time of 238 days (28–1218 days). For some patients, mul-
tiple post-surgical samples were taken (62 samples of 
serum and plasma each). Control samples were matched 
with patient samples based on sex and age. These samples 
came from a variety of sources including FCCC employ-
ees, individuals undergoing routine cancer screening, or 
spouses of patients. None of the patient samples used in 
this study overlap with our previous study [3].
Amino acid analysis
Serum amino acid levels for each sample were quantified 
using a Biochrom 30 amino acid analyzer as previously 
described [5]. Each sample was assayed once, as inter-day 
assay repeatability was previously established by process-
ing 27 different samples on two different days resulting 
in an average CV for all of the amino acids of 6.7% (range 
3.5–14.2%).
Data analysis
For univariate analysis, unpaired two-sided t tests were 
used with p < 0.05 being deemed significant with no cor-
rection for multiple testing. An unpaired test was deemed 
appropriate, as there was not one-to-one matching 
between cases and controls. One-way ANOVA, in com-
bination with Tukey’s LSD test, was used to determine 
differences between multiple groups. To identify the 
most predictive amino acids in either serum or plasma, 
forward step-wise regression was performed using all 25 
amino acids as variables. Because we observed minimal 
differences in ccRCC samples taken before and after sur-
gery, we combined these groups. At each step, the most 
predictive variable was included based on the Wald score. 
The final model contained only those variables with Wald 
scores with p < 0.05. All statistics were performed using 
Statistica 13 software (Dell Computer).
Results
Differences between PFAA and SFAA in controls
We initially examined SFAA and PFAA profiles in 124 
non-cancer controls (Fig.  1; Additional file  1: Table S2). 
Unexpectedly, there were large differences in the con-
centration of free amino acids in serum and plasma. Free 
amino acids were significantly reduced in plasma com-
pared to serum, with a mean reduction of 40%, with all 
amino acids showing highly significant p values. How-
ever, the magnitude of the differences varied quite widely, 
ranging from a 20% reduction (glutamine) to a whopping 
83% reduction (aspartate). The mean co-efficient of vari-
ation (CV) was quite similar between serum and plasma 
(32 vs. 31%, p  =  ns), suggesting that processing vari-
ability was not a factor. In ccRCC samples, the difference 
between serum and plasma was less, with a mean reduc-
tion of 23% (range 10–74%). The difference in behavior 
between control and RCC patients with regards to serum 
and plasma will be explored in more detail later.
SFAA and PFAA in ccRCC patients versus controls
We compared serum amino acid concentrations in con-
trols, ccRCC patients before surgery, and ccRCC patients 
after surgery (Fig.  2a; Additional file  1: Table S3). We 
found that the p value for the one-way ANOVA compar-
ing these three groups was significant (p < 0.05) for 22 of 
the 25 amino acids measured and was highly significant 
(p  <  0.0001) for 17 of these. Post-hoc testing revealed 
that, in almost all cases, the significance was driven by 
the difference between the controls and ccRCC samples 
(both pre- and post-surgery). In every case where the 
ANOVA was significant, ccRCC samples (combined pre- 
and post) had reduced concentrations of SFAA compared 
to controls with a mean reduction of 22%. The amino 
acids with the greatest percent decrease were glutamate, 
aspartate, serine, glycine, and ornithine. There were no 
statistically significant differences between ccRCC sam-
ples taken pre verse post surgery, although in 23 out of 25 
amino acids, the mean did rise slightly, i.e., moved toward 
the control values.
Results in plasma were somewhat different (Fig.  2b; 
Additional file  1: Table S4). The one-way ANOVA was 
significant (p < 0.05) for 14 plasma amino acids, and five 
were highly significant (p < 0.0001). Unlike serum, there 
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were at least three distinct patterns. Some amino acids 
(asparagine, ornithine, serine, and histidine) behaved 
similarly to serum, i.e. lower in both pre and post-surgi-
cal patients compared to controls. However, others (tryp-
tophan, arginine, cysteine, citrulline, leucine, isoleucine, 
valine, phenylalanine, and methionine) were elevated in 
patients compared to controls. Finally, three amino acids 
(proline, alanine, and homocysteine) were slightly ele-
vated only in post-surgical patient samples.
We also compared SFAA and PFAA profiles from indi-
viduals with early stage (I and II) versus late stage (III 
and IV) ccRCC. In both serum and plasma, we did not 
observe any statistically significant differences in any of 
the 25 amino acids (Additional file  1: Table S5). These 
findings indicate that alterations in PFAA and SFAA pro-
files are similar in both early and late stage ccRCC.
Interaction effect between plasma, serum, and cancer
Our univariate analysis showed significant differences 
between cancer patients and controls for a number of 
amino acids in both serum and plasma. However, many 
amino acids showed very different behaviors with regards 
to both the blood component and the ccRCC status. For 
example, arginine was decreased by 13% in the serum 
of ccRCC patients, but was increased by 33% in plasma. 
To explore this further, we performed 2-way ANOVA 
analysis for each amino acid, examining the contribu-
tion of blood component (serum or plasma), ccRCC 
status, and the interaction effect between them (Addi-
tional file 1: Table S6). The total amount of variance for 
each amino acid that could be explained by these three 
factors ranged from a low of 6.8% (α-aminobutyric acid) 
to a high of 65.9% (aspartate), with the mean being 35%. 
Twenty-three of the 25 amino acids examined had statis-
tically significant interaction terms, with the size of the 
interaction effect often being larger than the effect of iso-
lated ccRCC status. These findings indicate that for most 
amino acids, ccRCC status affects plasma and serum 
differently.
Modeling
We next performed forward-stepwise logistic regression 
to identify amino acids that could best separate ccRCC 
cases from controls for both serum and plasma. In 
serum, a six amino acid model including histidine, aspar-
agine, serine, arginine, glycine, and α-aminobutyric acid 
classified 89.8% of cases and 84.7% of controls accurately, 
giving a receiver operator area under the curve (ROC) of 
0.928 (Additional file 2: Fig. S1a). In plasma, the predic-
tive amino acids were tryptophan, asparagine, cysteine, 
arginine, aspartate, and serine (Additional file  2: Fig. 
S1b). These correctly classified 84.7% of cases and 83.1% 
of controls with an ROC of 0.917.
Based on the Wald statistic, the most significant amino 
acids were histidine in serum and tryptophan in plasma. 
A scatterplot of cases and controls shows impressive sep-
aration of cases and controls using these two variables 
(Fig. 3a). A logistic regression model using just these two 
measures correctly predicts 85.5% of the controls and 
84.7% of the cases with an ROC of 0.916 (Fig. 3b).
Discussion
Here, we examined PFAA and SFAA in patients with 
ccRCC, before and after surgery, and compared them 
to healthy controls. There were four important findings 
from this study that will be discussed below.
Fig. 1 Serum (n = 124) versus plasma (n = 124) relative amino acid concentrations in controls. All serum amino acids have been normalized to 1, 
while plasma levels for each amino acid are shown as a fraction of serum. Error bars show SEM
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First, we found that amino acid concentrations differ 
remarkably between plasma and serum. In our control 
patients, plasma had on average a 40% reduction in free-
amino acid concentrations compared to serum. This was 
a surprise to us, as serum is assumed to be equivalent 
to plasma without the clotting factors. In searching the 
literature, we were able to find only one other study [6] 
that examined the differences between serum and plasma 
using the same type of tubes (acid citrate) as the ones 
used here. This group also found that plasma had reduced 
free amino acid pools compared to serum, although our 
mean reduction was somewhat larger (27 vs. 40%). Why 
are free-amino acid levels so different between serum 
and plasma? One possibility is that the increased level of 
amino acids found in serum is due to the addition of the 
contents of platelets that are activated as part of the coag-
ulation process. Platelets that become activated release 
the contents of various granules into the bloodstream [7]. 
Lysosomes, which play a role in amino acid sensing and 
storage, are among the granules that are released [8]. If 
this idea is correct, our data suggests that the amount of 
amino acids present in these granules is not insignificant.
The second important finding is that there are large dif-
ferences in both the PFAA and SFAA profiles between 
ccRCC patients and controls. Our finding that the serum 
of ccRCC patients tend to have reduced levels of amino 
acids is consistent with our earlier study [3]. In the cur-
rent study, we found that 20 amino acids were decreased 
and zero increased in a statistically significant man-
ner, but in our previous study, only 13 amino acids were 
Fig. 2 Comparison of controls, pre‑surgery ccRCC and post‑surgery ccRCC samples. a Relative serum amino acid concentrations compared to 
control. b Relative plasma amino acid concentrations compared to controls. Error bars show SEM
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decreased and two were increased. A possible explana-
tion for the more robust results described here may be 
because the earlier study combined both ccRCC patients 
with other types of renal cancer including papillary, chro-
mophobe, and mixed sub-types, suggesting a more het-
erogeneous population. Unique to this study was our 
findings in plasma, which was not analyzed in the earlier 
study. Far fewer amino acids were altered in plasma, and 
the two showing the greatest difference (tryptophan and 
arginine) were actually elevated in the ccRCC patients. 
Logistic regression modeling indicates that serum did a 
slightly better job at classifying cases and controls than 
plasma. Impressively, a two-factor model using plasma 
tryptophan and serum histidine classified cases and con-
trols nearly as well as a six component plasma model and 
a six component serum model. One important weak-
ness of the current study is that we have only focused 
on ccRCC and do not know if other types of cancer may 
show similar alterations. Also, it is possible that altera-
tions in amino acids may be related to behavioral or die-
tary differences between patients and controls [9, 10].
A third important finding was that the differences 
between plasma and serum amino acid concentrations 
were differentially affected by ccRCC status. In controls, 
we saw 40% mean reduction in free amino acid concen-
trations in plasma compared to serum, but in ccRCC 
cases, there was only a 23% difference. Two-way ANOVA 
showed that there was a statistically significant interac-
tion effect between blood component and ccRCC status 
for 23 of the 25 amino acids. This finding suggests that 
ccRCC has unique effects on both serum and plasma, and 
that these effects are different in the different blood com-
ponents. The underlying reason behind this is not clear, 
but since the difference between plasma and serum con-
cerns clotting factors, it is possible that ccRCC patients 
may have some alterations in haemostatic factors. Inter-
estingly, high plasma fibrinogen levels predicted poorer 
outcome in a European cohort of non-metastatic renal 
cell carcinoma patients [11].
Finally, our most unexpected finding was that removal 
of the ccRCC tumor mass had minimal effect on the 
PFAA and SFAA profiles. In our previous paper, we had 
speculated that the generally lower levels of serum amino 
acids might be a reflection of the increased usage of 
amino acids by the tumor for biosynthetic processes [3]. 
However, our data here indicates that the tumor is not 
directly responsible, since our after surgery samples still 
show similar PFAA and SFAA profiles even though they 
have been debulked of their tumors. We can think of two 
possible explanations for this finding. First, it is possible 
that altered PFAA and SFAA profiles represent a sort of 
“ccRCC susceptibility profile,” i.e., people in the popula-
tion with these profiles are enriched in the sub-set that 
later develops ccRCC. In theory, this could be explored 
by examining PFAA and SFAA profiles in a prospec-
tive study design. Second, it is possible that the altered 
profiles represent some sort of secondary response 
to the cancer, which persists even after the cancer is 
removed. For example, one might imagine that some sort 
of immune response or inflammatory response to the 
Fig. 3 Scatter plot of serum histidine and plasma tryptophan for ccRCC samples and controls (a). Regression line for each group is shown (b)
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cancer persists even when the bulk of the offending anti-
gen has been removed.
Conclusions
In summary, our data shows that while both SFAA and 
PFAA profiles are altered in ccRCC patients compared 
to healthy controls, this alteration does not seem to be 
directly linked to tumor mass. Future studies will need 
to focus on whether differences in amino acid profiles are 
specific to ccRCC, or whether they occur in other types 
of cancers as well. Also, longitudinal studies studies will 
need to be performed to determine if a combination of 
serum histidine and plasma tryptophan might be a use-
ful as a biomarker for early detection of ccRCC or other 
cancers.
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